Ivabradine Attenuates Experimental Hepatic Fibrosis by Modulating Inflammatory and Apoptotic Signaling Pathways

Area of Science:

• Hepatology and Pharmacology
• Biomedical Research

Background:

• Hepatic fibrosis and cirrhosis are severe complications of liver injury with limited therapeutic options.
• Thioacetamide (TAA) is a common agent used to induce experimental liver fibrosis in animal models.

Purpose of the Study:

• To evaluate the hepatoprotective and antifibrotic effects of ivabradine in a rat model of thioacetamide-induced liver fibrosis.
• To investigate the molecular mechanisms underlying ivabradine's potential therapeutic actions.

Main Methods:

• Rats were induced with hepatic fibrosis using thioacetamide (TAA).
• Different groups received varying doses of ivabradine or a placebo concurrently with TAA administration.
• Biochemical markers, oxidative stress indicators, inflammatory markers, apoptotic markers, and fibrotic pathways were analyzed.

Main Results:

• TAA-induced liver injury was characterized by elevated liver enzymes, oxidative stress, inflammation, apoptosis, and collagen deposition.
• Ivabradine treatment dose-dependently improved liver function markers and restored oxidant/antioxidant balance.
• Ivabradine suppressed key pro-inflammatory (NF-κB p65/TNF-α) and fibrotic (PI3K/AKT/mTOR, TGF-β) pathways, and normalized apoptotic markers.

Conclusions:

• Ivabradine demonstrates significant antioxidant, anti-inflammatory, anti-apoptotic, and antifibrotic effects against TAA-induced liver fibrosis.
• The findings suggest ivabradine holds potential as a therapeutic agent for chronic liver diseases.
• Further clinical investigation is warranted to confirm these effects in human patients.